AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has received regulatory approval from the US Food and Drug Administration (FDA) for its respiratory drug Airsupra (albuterol + budesonide). The drug is now approved for the treatment or prevention of asthma symptoms and for the prevention of asthma attacks in adult patients. This decision was bolstered by Phase III clinical data which demonstrated that Airsupra has a similar onset of bronchodilation to albuterol alone and offers a superior reduction in the risk of severe asthma exacerbations.
Airsupra represents a first-in-class combination therapy, merging the short-acting beta2-agonist (SABA) albuterol with the inhaled corticosteroid (ICS) budesonide. This innovative combination works by relaxing the smooth muscles of the airways and decreasing lung inflammation, providing a dual-action approach to asthma management.
In a press release, AstraZeneca detailed the launch of a co-pay assistance program in the US aimed at alleviating the financial burden on patients seeking treatment with Airsupra.- Flcube.com
